🇺🇸 FDA
Patent

US 7309692

Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1

granted A61KA61K38/00A61K48/00

Quick answer

US patent 7309692 (Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1) held by The Board of Regents of the University of Texas System expires Mon Dec 13 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Dec 18 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 13 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K38/00, A61K48/00, A61P, A61P35/00